StockData
Aktis Oncology, Inc. logo

Aktis Oncology, Inc. (AKTS) company profile

AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$16.31+0.15 (+0.93%)

Close on Nov 17, 2026Market cap $907.15MP/E –Yield –

About Aktis Oncology

Pharmaceutical Preparations, SIC 2834

Aktis Oncology, Inc. is a clinical-stage biopharmaceutical company that develops targeted radiopharmaceuticals to treat solid tumors. The company utilizes a proprietary miniprotein radioconjugate platform to bind radioisotope payloads, such as alpha-emitting actinium-225, to cancer cells while rapidly clearing normal tissues. Its lead product candidate, [225Ac]Ac-AKY-1189, targets Nectin-4-expressing cancers, including urothelial cancer and other solid tumors such as lung, breast, colorectal, and cervical malignancies. Another candidate in development, [225Ac]Ac-AKY-2519, targets B7-H3-expressing tumors such as prostate and lung cancers. The company also maintains early-stage discovery programs and a research collaboration with Eli Lilly. Its target patients are individuals diagnosed with solid tumor cancers expressing these specific tumor markers.

The company is based in the United States, with corporate headquarters located in Boston, Massachusetts. Its operations include a multi-site clinical trial network across the United States, along with research and development facilities. Aktis Oncology works with domestic and international suppliers and contract manufacturers for isotope sourcing and drug manufacturing.

Summary of the business section of Aktis Oncology's latest annual report, written by StockData.

Company profile

Company

Legal name
Aktis Oncology, Inc.
Headquarters
Boston, MA
Address
17 Drydock Avenue, Suite #17-401 02210
Phone
(978) 237-4380
Employees
79, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31

Stock & identifiers

Ticker
AKTS
Exchange
Nasdaq
IPO date
Jan 9, 2026
Shares outstanding
56M, Jul 31, 2026
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
2035832
CUSIP
01021M104
ISIN
US01021M1045
FIGI
BBG00ZQS8KZ1
Share class FIGI
BBG00ZQS8L07
EIN
85-2584233

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Matthew RodenPresident and CEO, Director91,998
Akos CzibereChief Medical Officer0
Shulamit Ron-BiggerChief Operating Officer34,200
Paul L. FeldmanChief Scientific Officer144,568
Kyle D. KuvalankaChief Financial Officer–
Ken HerrmannDirector3,506
Glenn GormleyDirector–
Todd FoleyDirector4,002,533
Helen Susan KimDirector5,671,825
Oleg NodelmanDirector433,527
EcoR1 Capital, LLCDirector–
Lloyd Mitchell SegalDirector19,631
Michael A. ShermanDirector–
Mary ThistleDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jan 9, 2026
Offer price
$18.00
Securities offered
17,650,000
Gross proceeds
$317.70M
Exchange
Nasdaq
Lock-up ends (est.)
Jul 8, 2026

“Per share Total Initial public offering price $ 18.00 $ 317,700,000 Underwriting discounts and commissions (1) $ 1.26 $ 22,239,000 Proceeds before expenses, to Aktis Oncology, Inc.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?